Ultragenyx Names Board Member
This article was originally published in Scrip
Ultragenyx Pharmaceutical Inc. has appointed Sofinnova Ventures' executive partner Lars Ekman to its board as an independent director – effective since March 17, 2016. Prior to Sofinnova Ventures Ekman was president of R&D at Elan and previously he held various senior scientific and clinical roles at Pharmacia (acquired by Pfizer Inc.). Currently Ekman is chair of Amarin Corporation Plc., Sophiris Bio Inc., and Prothena Corporation Plc. and is a director of Spark Therapeutics Inc.